News

Strategic Partnership between Teva and Kowa Pharmaceutical

Jerusalem and Tokyo
Sep 23, 2008

Teva Pharmaceutical Industries Ltd. and Kowa Company, Ltd. entered into an agreement to establish a generic pharmaceutical company in Japan. The company named as Teva-Kowa Pharma Co.Ltd. would target the Japanese market as a supplier of generic pharmaceutical products by leveraging the marketing, research and development, manufacturing and distribution capabilities of each company. Teva-Kowa Pharma, will become operational in 2009 with each of the parent company holding 50% stake.
 
"Combining Kowa's knowledge of and established reputation within the Japanese market with Teva's global leadership and expertise in generics should enable us to maximize the opportunity available in this important growth market," said Shlomo Yanai, Teva's President and Chief Executive Officer. Yoshihiro Miwa, Kowa's President and Chief Executive Officer, added, “The strategic alliance between Kowa and Teva will leverage both companies' respective strengths to meet the needs of medical institutions and patients for high quality and cost-effective generic pharmaceuticals.”